23andMe Paves the Way for Direct-to-Consumer Genetic Health Risk Tests of Limited Clinical Utility

In April 2017, the U.S. Food and Drug Administration authorized 23andMe's direct-to-consumer (DTC) genetic test. This commentary discusses its limited clinical utility and raises concerns that its approval creates a pathway that could lead to expansive DTC genetic testing of similarly low clinical utility that the public will misunderstand and misuse.

http://ift.tt/2sf5UQv